Fatty Liver Disease

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously referred to as non-alcoholic fatty liver disease, is a chronic condition in which excess fat accumulates in the liver in the setting of metabolic risk factors such as obesity, insulin resistance, and lipid disorders. In some individuals, MASLD progresses to metabolic dysfunction-associated steatohepatitis (MASH), a more advanced stage marked by inflammation and injury of the liver. Over time, this can lead to fibrosis, cirrhosis, and increased risk of liver cancer, while also significantly increasing cardiovascular risk.

The landscape of fatty liver disease management is evolving rapidly, with major advances in diagnostics and emerging pharmacologic therapies. At Advocare Princeton Cardiometabolic Health, we integrate these advances into care, using tools such as noninvasive imaging and biomarker assessments, to track liver health and progression risk. Our therapeutic strategies are designed not only to improve liver outcomes but also to address the broader metabolic syndrome, protecting multiple organ systems and aligning with the latest evidence-based practices to optimize long-term health and quality of life.